Combining IL-21 and Low-Dose IL-2 for Cancer Treatment
Author Information
Author(s): He Hong, Wisner Preya, Yang Guojun, Hu Hong-Ming, Haley Dan, Miller William, O'Hara Aisling, Alvord W Gregory, Clegg Christopher H, Fox Bernard A, Urba Walter J, Walker Edwin B
Primary Institution: Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland OR, USA
Hypothesis
Can the combination of IL-21 and low-dose IL-2 enhance anti-tumor immunity in a murine melanoma model?
Conclusion
The combination of IL-21 and low-dose IL-2 significantly improved long-term tumor-free survival in mice with melanoma.
Supporting Evidence
- IL-21 alone and IL-2 alone both delayed tumor progression.
- Combination therapy with IL-21 and IL-2 resulted in the highest long-term tumor-free survival frequency of 46%.
- Animals that were tumor-free for > 150 days demonstrated tumor-specific protection after rechallenge.
Takeaway
Researchers found that using two special proteins together helped mice fight off cancer better than using either one alone.
Methodology
Mice with melanoma were treated with IL-21 and low-dose IL-2 after being vaccinated with a tumor antigen, and their tumor growth and survival were monitored.
Limitations
The study was conducted in a murine model, which may not fully replicate human responses.
Participant Demographics
Congenic C57BL/6 (Ly5.2) mice, both male and female, aged 10-16 weeks.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website